Coeptis Therapeutics (NASDAQ:ZSQR) Shares Gap Down – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $14.71, but opened at $13.11. Coeptis Therapeutics shares last traded at $13.15, with a volume of 5,389 shares traded.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The company has a 50 day simple moving average of $12.38 and a 200-day simple moving average of $12.76. The firm has a market cap of $627.45 million, a PE ratio of -4.84 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Trading of Coeptis Therapeutics

Several hedge funds have recently added to or reduced their stakes in ZSQR. Steward Partners Investment Advisory LLC grew its stake in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the period. State Street Corp lifted its stake in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics in the 3rd quarter valued at about $140,000. Finally, Marshall Wace LLP purchased a new stake in Coeptis Therapeutics during the 4th quarter valued at about $259,000. 13.88% of the stock is owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.